Rapid Dose Therapeutics and Thrive Cannabis Sign Manufacturing Agreement for QuickStrip™ Cannabis Products

BURLINGTON, ON and BRANTFORD, ON, Aug. 8, 2019 /CNW/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT") announced today that they have signed a Manufacturing Agreement ("the Agreement") with Thrive Cannabis ("Thrive") to produce QuickStrip™ cannabis products for both the Canadian medical and recreational markets. This Agreement represents a continuation of the RDT growth strategy.

RDT’s proprietary QuickStrip™ technology is a smoke-free, sublingual, fast-dissolving drug delivery system that offers an Anytime, Anywhere™ product for medical and recreational consumers.

“We are demonstrating our ongoing commitment to providing consumers in the Canadian medical and recreational cannabis markets a Smoke-Free Choice™ with a proprietary delivery technology that is Quick, Convenient, Precise and Discreet™,” said Mark Upsdell, CEO of RDT. “RDT will continue to expand our strategic partnerships and further strengthen our unique delivery leadership position within the cannabis sector. This agreement with Thrive proves that QuickStrip™ is a desirable technology and delivery option for Canadian consumers, while simultaneously offering health benefits and improving consumer outcomes,” added Upsdell.

Thrive expects to allocate a significant proportion of its high-quality processed distillate to the production of QuickStrip™, launching under its first brand, GreyBeard and then following with a women-focused QuickStrip™ product. Thrive will also take on new medical and consumer brand production for other Canadian licensed producers.

Todd Masse, Thrive CCO, states “This Agreement enables Thrive to ensure complete coverage and demand fulfillment where gaps may have otherwise existed.  All Canadians should have access to the QuickStrip™ delivery technology. The Agreement with RDT will enable Thrive to provide QuickStrip™ product to a wide cannabis consumer base across Canada. QuickStrip™ allows us to offer consumers and patients a No Smoke. No Smell. No Stigma™ product.” Masse continues, “In the coming weeks we will be evaluating white label opportunities with other leading cannabis organizations.”

About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT’s QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.

For more information, visit: www.rapid-dose.com

FOR MEDIA & PR INQUIRIES
Please Contact: Media Relations